# NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

> **NCT06079333** · PHASE2 · RECRUITING · sponsor: **Leiden University Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Anaplastic Thyroid Cancer

## Interventions

- **DRUG:** dabrafenib/trametinib

## Key facts

- **NCT ID:** NCT06079333
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06079333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06079333, "NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06079333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*